Pluri (DB:4DX) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

4DX Stoklara Genel Bakış

A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.

Şirket hakkında

4DX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 3.6% oranında arttı

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $341K )

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €27M )

Hissedarlar geçen yıl sulandırıldı

Pluri Inc. Rakipler

2invest

XTRA:2INV

€59.8m

Medigene

XTRA:MDG1

€27.6m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€124.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Pluri
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$5.60
52 Haftanın En Yüksek Seviyesi	US$7.32
52 Haftanın En Düşük Seviyesi	US$3.10
Beta	1.62
11 Aylık Değişim	0%
3 Aylık Değişim	-10.83%
1 Yıllık Değişim	1.45%
33 Yıllık Değişim	-79.24%
5 Yıllık Değişim	-86.89%
Halka arzdan bu yana değişim	-76.74%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	4DX	DE Biotechs	DE Pazar
7D	0%	0.7%	1.1%
1Y	1.4%	-8.5%	18.9%

Getiri vs. Endüstri: 4DX geçen yıl % -15.1 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 4DX geçen yıl % 13.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 4DX's price volatile compared to industry and market?
4DX volatility
4DX Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 4DX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 4DX 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2001	129	Yaky Yanay	www.pluri-biotech.com

Pluri Inc. Temel Bilgiler Özeti

Pluri'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
4DX temel i̇stati̇sti̇kler
Piyasa değeri	€24.83m
Kazançlar(TTM)	-€20.13m
Gelir(TTM)	€317.54k

78.2x

P/S Oranı

-1.2x

F/K Oranı

4DX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
4DX gelir tablosu (TTM)
Gelir	US$341.00k
Gelir Maliyeti	US$9.00k
Brüt Kâr	US$332.00k
Diğer Giderler	US$21.95m
Kazançlar	-US$21.62m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.01
Brüt Marj	97.36%
Net Kâr Marjı	-6,339.59%
Borç/Özkaynak Oranı	1,304.3%

4DX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

4DX Stoklara Genel Bakış

Ödüller

Risk Analizi

Pluri Inc. Rakipler

XTRA:2INV

€59.8m

XTRA:MDG1

€27.6m

XTRA:CNW

€6.5m

XTRA:HPHA

€124.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Recent updates

Nasdaq Grants Extension Till Nov. 24 to Pluri Inc. to Regain Compliance with Stockholder Equity Requirement

Pluri Inc. Announces Executive Changes, Effective September 30, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

High number of new directors

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought €126k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Independent Director Isaac Braun has left the company

Insider recently sold €1.3m worth of stock

Insider recently sold €84k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

New 90-day low: €4.30

Revenue in line with expectations

Pluristem Therapeutics Inc. Announces Board Appointments

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

New 90-day high: €9.75

Insider recently bought €162k worth of stock

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

New 90-day low: €7.20

Revenue in line with expectations

Insider recently bought €158k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

New 90-day high: €9.40

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought €269k worth of stock

Full year earnings released - €1.60 loss per share

New 90-day high - €9.30

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Pluri Inc. Temel Bilgiler Özeti

78.2x

-1.2x

Kazanç ve Gelir